首页> 外文OA文献 >A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease

【2h】

A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease

机译：一项随机，双盲，四路，交叉试验，比较了慢性阻塞性肺疾病患者每日一次和每日两次用新型长效β2-激动剂奥洛他特罗治疗的24小时FEV1曲线

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Joos Guy F.; Aumann Joseph-Leon; Coeck Carl; Korducki Lawrence; Hamilton Alan L.; Kunz Christina; Aalbers René;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting beta(2)-agonist, in patients with chronic obstructive pulmonary disease [J] . Joos Guy F., Aumann Joseph-Leon, Coeck Carl, Respiratory medicine . 2015,第5期

机译：一项随机，双盲，四路，交叉试验，比较了慢性阻塞性肺病患者每天一次和每天两次用新型长效β（2）激动剂奥洛他特罗治疗的24小时FEV1曲线疾病
2. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting beta(2)-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease [J] . Maleki-Yazdi M. Reza, Beck Ekkehard, Hamilton Alan L., Respiratory medicine . 2015,第5期

机译：每日一次用新型长效β（2）激动剂奥洛他特罗治疗慢性阻塞性肺疾病的患者的随机，安慰剂对照II期剂量范围试验，为期4周
3. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease [J] . Beeh Kai-Michael, Westerman Jan, Kirsten Anne-Marie, Pulmonary pharmacology & therapeutics . 2015,第Null期

机译：每日一次噻托铵和奥洛他罗固定剂量联合治疗慢性阻塞性肺疾病的24小时肺功能概况
4. Dose-finding evaluation of once-daily treatment with olodaterol a novel long-acting β2-agonist in patients with asthma: results of a parallel-group study and a crossover study [O] . Paul M. O’Byrne, Tony D’Urzo, Ekkehard Beck, 2015

机译：新型长效β2受体激动剂奥洛他特尔每日一次治疗哮喘患者的剂量发现评估：平行研究和交叉研究的结果
5. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV₁ profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β₂-agonist, in patients with chronic obstructive pulmonary disease [O] . Joos Guy, Aumann Joseph-Leon, Coeck Carl, 2015

机译：一项随机，双盲，四向，交叉试验，比较24小时FEV 1曲线，每日一次与每日两次用慢性阻塞性肺病患者使用新型长效β-激动剂奥达特罗治疗

A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease

著录项

相似文献

相关主题

期刊订阅